WO2002000258A1 - Compositions medicales de therapie angiogenique - Google Patents
Compositions medicales de therapie angiogenique Download PDFInfo
- Publication number
- WO2002000258A1 WO2002000258A1 PCT/JP2001/005514 JP0105514W WO0200258A1 WO 2002000258 A1 WO2002000258 A1 WO 2002000258A1 JP 0105514 W JP0105514 W JP 0105514W WO 0200258 A1 WO0200258 A1 WO 0200258A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- gene
- hgf
- angiogenesis
- pharmaceutical composition
- substance
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/52—Isomerases (5)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/558—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
- A61K31/5585—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes having five-membered rings containing oxygen as the only ring hetero atom, e.g. prostacyclin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1833—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1858—Platelet-derived growth factor [PDGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Definitions
- composition for angiogenesis therapy is provided.
- the present invention relates to novel pharmaceutical compositions for angiogenesis therapy. More specifically, the present invention relates to a substance having a vasodilatory action and a Z or Migaki or platelet aggregation inhibitory action,
- the present invention relates to a novel pharmaceutical composition for angiogenesis therapy, comprising, as active ingredients, at least one selected from substances producing the substance and a gene encoding an angiogenic factor.
- the present invention also relates to novel adaptation of the prosulin cyclin synthase gene and the ets-1 gene to angiogenesis therapy.
- New blood vessel development and angiogenesis are initiated with the activation of endothelial cells in the parent blood vessel, but not only stimulate this angiogenesis in vivo, but also act mitogenically on endothelial cells in vitro.
- the growth factors that are used are called "angiogenic factors (angiogenic growth factors)”.
- angiogenic factors such as fibroblast growth factor (FGF) family (Science 257,140 1-1403 (1992), Nature 362,844-846 (1993)), endothelial cell growth factor (EGF) ( J. Surg. Res. 54, 575-583 (1993)) and vascular endothelial growth factor (VEGF) to promote and / or enhance collateral circulation in animal models of myocardial and lower limb ischemia.
- FGF fibroblast growth factor
- EGF endothelial cell growth factor
- VEGF vascular endothelial growth factor
- HGF hepatocyte growth factor acts as an endothelium-specific growth factor in the same manner as VEGF (J. Hypertens. 14, 1067-1072 (1992). 6)).
- angiogenesis therapy The strategy of using angiogenic factors as described above to treat vascular disorders has been termed "angiogenesis therapy".
- angiogenesis therapy for ischemic disease and arterial disease using the angiogenesis factor gene as described above has been actively studied.
- the present inventors have clarified the effectiveness of the HGF gene for arteriosclerosis obliterans (AS0) (Circulation, Vol. 100, ⁇ .18, ⁇ .1672 (1999), Japanese Circulation Journal Vol. 64). 3 Suppl. I, p478 3 No. P079 (2000)). It has been shown that the HGF gene effectively acts on ischemia-reperfusion injury in myocardial infarction (Circulation, Vol. 96, No. 8, No. 3459 (1997), Ann. Thorac. Surg. , 67, pi 726 -1731 (1999), Gene Therapy, 7: 417-427 (2000)).
- prostaglandin I 2 is a type of prostaglandin prosulfuron evening cyclin (prostaglandin I 2; PGI 2).
- PGI 2 prostaglandin I 2
- Is unstable lipid Medeie half-life 5-10 minutes Isseki is one (Arch Gynecol.0bstet 3 243, pl87-190 (1988), it is known that a potent vasodilatory action and a platelet aggregation inhibitory action are exhibited by increasing the cAMP level via a G protein-coupled receptor (N. Engl. . J. Med.
- vasodilators such as PGI 2 and PGEi (prostaglandins and their derivatives (analogs)) are now widely used in the treatment of various vascular disorders, ie AS0 and For peripheral blood circulation disorders such as TA0 (occlusive thromboangiitis), PGE! Is administered intra-arterially or intravenously with the expectation of effects such as vasodilation and platelet aggregation. Since PGI 2 has a strong action and deactivates very quickly, various derivatives (such as oral prost and peraprost sodium) have been developed, and these are peripheral blood vessel obstructions.
- various derivatives such as oral prost and peraprost sodium
- substances having a vasodilating action or a platelet aggregation inhibitory action such as PG 1 2 are known to be effective against a variety of vascular disorders.
- these substances have never been used in combination in the aforementioned angiogenesis therapy using the HGF gene and the like, and what kind of efficacy occurs is not disclosed at all.
- HGF VEGF vascular endothelial growth factor
- bFGF vascular endothelial growth factor
- EGF angiogenic factor
- HGF VEGF vascular endothelial growth factor
- bFGF vascular endothelial growth factor
- EGF angiogenic factor
- HGF VEGF vascular endothelial growth factor
- bFGF vascular endothelial growth factor
- EGF erythroblastosis virus oncogene homo lo 1
- the factor is activated (J. Cell. Physiol., 169, 522-531 (1996), Molecular Medicine of HGF, Medical Review, 179-185 (1998)).
- the et s-1 gene has never been used in angiogenesis therapy, and its effect has not been clarified at all. Disclosure of the invention An object of the present invention is to provide a novel pharmaceutical composition for angiogenesis therapy.
- the present invention provides, as an active ingredient, a substance having a vasodilatory action and / or an inhibitory action on platelet aggregation, and at least one selected from substances producing the substance, and a gene encoding an angiogenic factor.
- An object of the present invention is to provide a novel pharmaceutical composition for angiogenesis therapy, comprising: Another object of the present invention is to provide a novel adaptation of the prosylcycline synthase gene or the ets-1 gene to angiogenesis therapy.
- the present inventors have, or in angiogenesis therapy with HGF gene, an enzyme that synthesizes PGI 2 (PGI 2 synthetase, hereinafter referred to as PGIS) in case that a combination of genes, indicate what effect was considered.
- PGIS PGI 2 synthetase
- the combination of the HGF gene or VEGF gene and the PGIS gene unexpectedly and significantly improved lower limb blood flow compared to the case of using each gene alone. It became clear to do. Furthermore, for the first time, it has been found that the PGIS gene enhances the angiogenic action of the HGF gene or the VEGF gene, and also has an angiogenic action by itself. Based on the above results, in angiogenesis therapy using a gene for an angiogenic factor, it is extremely difficult to use a substance having a vasodilatory or platelet aggregation-inhibiting action such as PGI 2 or a substance producing the substance such as the PGIS gene in combination. It turned out to be effective.
- a substance having a vasodilatory or platelet aggregation-inhibiting action such as PGI 2 or a substance producing the substance such as the PGIS gene in combination. It turned out to be effective.
- the present inventors also examined the application of the gene encoding the transcription factor ets-1 located downstream of HGF and VEGF signaling to angiogenesis therapy.
- the administration of the ets_l gene which is a transcriptional regulator, alone showed an angiogenic effect.
- 6 se 3 — 1 genetic It was clarified that the combined use of the offspring and the HGF gene showed a more remarkable angiogenesis effect as compared with the case where each was administered alone.
- the present invention has been completed based on the above findings.
- the gist of the present invention is:
- a blood vessel containing, as active ingredients, at least one selected from a substance having a vasodilatory action and / or a platelet aggregation inhibitory action, and a substance producing the substance, and a gene encoding an angiogenic factor.
- a pharmaceutical composition for neoplasia is a pharmaceutical composition for neoplasia,
- At least one selected from a substance having a vasodilatory action and / or an inhibitory action on platelet aggregation and a substance producing the substance is used in combination with a gene encoding an angiogenic factor.
- angiogenesis therapy comprising, as active ingredients, at least one selected from a substance having a vasodilatory action and a platelet aggregation inhibitory action, and a substance that produces the substance, and a gene encoding an angiogenic factor.
- a blood vessel characterized in that at least one selected from a substance having a vasodilatory action and a platelet aggregation inhibitory action and a substance that produces the substance is used in combination with a gene encoding an angiogenic factor.
- a substance having a vasodilatory action and / or a platelet aggregation inhibitory action, and a substance that produces the substance is a substance involved in increasing cAMP;
- the substance for producing a substance having a vasodilatory action and / or a platelet aggregation inhibitory action is in the form of a gene, which is used for angiogenesis therapy according to any one of (1) to (6) above.
- composition for angiogenesis therapy according to (7), wherein the gene is a proscine cyclin synthase gene; (9) a pharmaceutical composition for angiogenesis therapy, comprising an HGF gene and a proscine cyclin synthase gene as active ingredients;
- composition for angiogenesis therapy which comprises using an HGF gene and a proscine cyclin synthase gene in combination.
- a pharmaceutical composition for angiogenesis therapy which contains a VEGF gene and a proscine cyclin synthase gene as active ingredients;
- a pharmaceutical composition for angiogenesis therapy which comprises using a VEGF gene and a proscine cyclin synthase gene in combination;
- composition for angiogenesis therapy according to any one of (1) to (14), wherein the gene is introduced in the form of naked DNA.
- Angiogenesis by a gene encoding an angiogenic factor, which comprises, as an active ingredient, a substance having a vasodilatory action and / or a platelet aggregation inhibitory action, and at least one selected from substances that produce the substance. Enhancer,
- Enhancement of angiogenesis by a gene encoding a vascular growth factor which comprises, as an active ingredient, a substance having a vasodilatory action and a platelet aggregation inhibitory action, and a substance that produces the substance.
- a vascular growth factor which comprises, as an active ingredient, a substance having a vasodilatory action and a platelet aggregation inhibitory action, and a substance that produces the substance.
- the substance having a vasodilatory action and / or an inhibitory action on platelet aggregation, and the substance producing the substance is a substance involved in the increase of cAMP.
- angiogenesis agent comprising a proscine cyclin synthase gene as an active ingredient
- a pharmaceutical composition for angiogenesis therapy comprising as an active ingredient the ets-1 gene and another gene encoding an angiogenic factor;
- a pharmaceutical composition for angiogenesis therapy which comprises using the ets-1 gene in combination with another gene encoding an angiogenic factor;
- a pharmaceutical composition for angiogenesis therapy comprising an HGF gene and an ets-1 gene as active ingredients;
- a pharmaceutical composition for angiogenesis therapy which comprises using an HGF gene and an ets-1 gene in combination;
- the enhancer of angiogenesis according to (31), wherein the angiogenic factor is HGF and / or VEGF; (33) an enhancer of angiogenesis by the HGF gene, comprising an et s-1 gene as an active ingredient;
- An angiogenic agent comprising the et s-1 gene as an active ingredient, and (36) The angiogenic agent according to (35), which is used for treating or preventing ischemic disease or arterial disease.
- the present invention comprises, as an active ingredient, a substance having a vasodilatory action and / or an inhibitory action on platelet aggregation, at least one selected from substances producing the substance, and a gene encoding an angiogenic factor. It is intended to provide a pharmaceutical composition for angiogenesis therapy.
- the term "gene encoding an angiogenic factor” used in angiogenesis therapy refers to a gene encoding a protein, polypeptide, or a part thereof capable of inducing the formation of new blood vessels.
- HGF HGF
- VEGF vascular endothelial growth factor
- VEGF-2 acidic FGF
- bFGF basic FGF
- FGF-4 EGF
- TGF-H TGF- / ?
- PD platelet-derived endothelial cell growth factor
- PD Genes encoding ECGF
- PDGF platelet-derived growth factor
- TNF-H tumor necrosis factor-1
- insulin-like growth factor insulin-like growth factor
- angiopoietin-11 angiopoietin-11.
- genes encoding transcription factors such as HIF-1 which controls the expression of genes such as VEGF, or the ets family including et s-1, and the like.
- HGF gene and the VEGF gene are used, and more preferably, the HGF gene is used.
- the gene sequences of these genes are registered in public databases, and those skilled in the art can easily clone the above genes by using them.
- HGF gene and VEGF gene will be described as examples.
- the “HGF gene” encodes HGF (HGF protein). Gene.
- HGF gene a product obtained by incorporating the HGF gene into an expression plasmid so that it can be expressed may be simply referred to as “HGF gene”. Specifically, Nature, 342,440 (1989), Patent No. 2777678, Biochem.Biophys.Res.Commun., 163, 967 (1989), etc.
- Non-viral vectors viral vectors
- the nucleotide sequence of the cDNA encoding HGF is described in the above-mentioned literature, and is also registered in databases such as Genbank. Therefore, based on these sequence information, an appropriate DNA portion is used as a primer for PCR, for example, by performing a T-PCR reaction on mRNA derived from the liver or leukocytes to clone 0008. can do.
- These closings are, for example, molecular
- the HGF gene of the present invention is not limited to those described above, and can be used as the HGF gene of the present invention as long as the expressed protein is a gene having substantially the same angiogenic action as HGF. That is, 1) a DNA that hybridizes with the c ′ DNA under stringent conditions, or 2) one or more (preferably several) amino acids with respect to the amino acid sequence of the protein encoded by the cDNA. DNA encoding a protein comprising a substituted, deleted and / or added amino acid sequence, and the like, as long as they encode a protein having an angiogenic effect, are included in the category of the HGF gene of the present invention. .
- the DNAs of the above 1) and 2) can be easily obtained by, for example, site-directed mutagenesis, PCR, or a conventional hybridization method. This can be done with reference to the basic book.
- VEGF gene refers to a gene encoding VEGF protein.
- the VEGF gene incorporated into an expression plasmid so that it can be expressed may be simply referred to as “VEGF gene”.
- VEGF gene a gene encoding VEGF protein.
- the VEGF gene incorporated into an expression plasmid so that it can be expressed may be simply referred to as “VEGF gene”.
- VEGF gene a gene encoding VEGF protein.
- VEGF gene incorporated into an expression plasmid so that it can be expressed may be simply referred to as “VEGF gene”.
- VEGF gene Specifically, VE An example is one in which the GF cDNA is incorporated into an appropriate expression vector (non-viral vector, virus vector) as described below.
- the presence of four subtypes (VEGF21, VEGF165, VEGF189, VEGF206) of the VEGF gene in humans due to alternative splicing during transcription has been reported (Science, 219,
- any of these VEGF genes can be used, but the VEGF165 gene is more preferable from the viewpoint of being most biologically active. Further, as in the case of the above-mentioned HGF, even if these VEGF genes are modified, etc., as long as they encode a protein having an angiogenic action, the category of the VEGF gene of the present invention is not limited. include.
- the VEGF gene can be easily cloned by those skilled in the art based on sequences described in literature (eg, Science, 246, 1306 (1989)) and sequence information registered in a database. It can also be easily modified.
- HGF gene vascular endothelial growth factor gene
- VEGF gene or a gene encoding a variant thereof as described above has an angiogenic effect
- the proliferative effect on endothelial cells can be examined in ft in vivo by measuring the effect of improving blood flow on a mouse lower limb ischemia model described in Examples below.
- the genes encoding the angiogenic factors as described above may be used alone or in combination in the angiogenesis therapy of the present invention.
- PGI 2 synthesized by PGIS has a vasodilating action, a vascular permeability enhancing action, and a platelet aggregation inhibiting action, as described above.
- the reason for the synergistic effect is that the combined use of the HGF gene and the PGIS gene allows HGF to be expressed at the ischemic site through the effects of PGI 2 such as vasodilatory action and platelet aggregation inhibitory action. It is considered that an environment in which HGF easily acts, that is, an environment in which HGF easily undergoes angiogenesis is provided, and as a result, an unexpected effect as described above has occurred.
- a substance having a vasodilatory action and / or an inhibitory action on platelet aggregation, or a substance that produces the substance can exert the same combined effect as the PGIS gene. Therefore, in the present invention, a substance having a vasodilatory action and a Z or platelet aggregation inhibitory action, and at least one selected from substances producing the substance, and a gene encoding an angiogenic factor are contained as active ingredients.
- a pharmaceutical composition for angiogenesis therapy is contained as active ingredients.
- a substance having both a vasodilatory action and a platelet aggregation inhibitory action, and a substance that produces the substance are suitably used in the angiogenesis therapy of the present invention.
- the term “substance having a vasodilatory effect” includes all known substances having a vasodilatory effect (such as commercially available vasodilators), and may be any substance such as a gene, a protein, or a low-molecular compound. May be. Specifically, the following are exemplified.
- common vasodilators include Ca antagonists, ACE inhibitors, HI-1 blockers, ANP (Atrial Natriuretic Peptide ⁇ atrial natriuretic peptide), power channel openers, and hydralazine. are mentioned.
- vasodilator used in AS0 for example, PGI 2 and PGE ⁇ there have these derivatives (iloprost, beraprost sodium, l ip OPGE ⁇ ) other prostaglandin formulations include such, including nitroglycerin NO donors such as nitrites or drugs that increase intracellular c GMP concentration Drugs that increase intracellular c AMP, such as phosphogesterase inhibitors, and the like.
- the agent increases the c AMP or prosulfuron evening prostaglandin formulations, and more preferably PGI 2, PGEi and derivatives thereof (analogs), and more preferably include PG 1 2 derivatives.
- the term “substance having a platelet aggregation inhibitory effect” includes all known substances having a platelet aggregation inhibitory effect (eg, commercially available antiplatelet agents), and includes any substance such as genes, proteins, and low molecular weight compounds. It may be. Specific examples include prostaglandin preparations such as PGI 2 or PGE or derivatives thereof (iloprost, beraprostonatrium, lipoPGE, etc.), as well as arachidonic acid metabolism inhibitors, adenylate cyclase promoters, phosphodiesterase III inhibitors, 5-HT 2 receptions evening one antagonist, Arakidon acid metabolism inhibitor, Oh Rui include phosphodiesterase V inhibitors, and the like.
- PGI 2 or PGE or derivatives thereof iloprost, beraprostonatrium, lipoPGE, etc.
- arachidonic acid metabolism inhibitors such as PGI 2 or PGE or derivatives thereof (iloprost, beraprostonatrium, lipoPGE, etc
- the agent increases the c AMP or prostaglandin formulations, and more preferably PGI 2, PGEi and these stable derivatives (analogs), even more preferably include PG 1 2 derivatives.
- the term "substance which produces a substance having a vasodilatory action and / or platelet aggregation inhibitory action” means a substance which synthesizes, produces or induces a substance having the aforementioned vasodilatory action and / or platelet aggregation inhibitory action. I do. Specifically, it refers to a substance that synthesizes, produces or induces the substance that increases prostaglandin or cAMP.
- the substance may be any substance such as a gene, a protein, a low molecular weight compound, etc.
- a synthetic enzyme for synthesizing a vasodilator it is preferably used in the form of a gene.
- the gene include, for example, the PGIS gene, the sic xygenase-1 (COX-1) gene, and the cyclooxygenase-2 (COX-2) gene (Proc. Natl. Acad.
- PGIS gene PGIS gene
- COX-1 gene and COX-2 gene are used, and more preferably, the PGIS gene is used. All of these genes have their gene sequences registered on a public basis and can be easily cloned by those skilled in the art using these genes.
- PGIS gene will be described as an example.
- the “PGIS gene” refers to a gene encoding a PGIS protein.
- a gene obtained by incorporating the PGIS gene into an expression plasmid so that it can be expressed is sometimes simply referred to as a “PGIS gene”.
- the cDNA of PGIS described in BBRC, Vol. 200, No. 3, pl728-1734 (1994) and WO 95/30013 is converted into an appropriate expression vector (non-viral vector, Virus vector).
- the PGIS gene can be easily cloned by a person skilled in the art based on the sequence described in the literature and the sequence information registered in the database, and its modification can be easily performed. Can be done.
- the fact that the protein encoded by the gene has the desired PGIS ′ activity can be confirmed, for example, by using Enzymnoassay using ⁇ 6-keto Prostaglandin Fl enzyme immunoassay kit (manufactured by Cayman, catalog number # 515211).
- metabolites of proscycycline synthase can be measured by a method such as detection by thin layer chromatography (TLC).
- TLC thin layer chromatography
- the substance having the vasodilatory action and / or platelet aggregation inhibitory action as described above, or a substance which produces the substance may be used alone in angiogenesis therapy using an angiogenic factor gene, Alternatively, a plurality of them may be used in combination.
- the dosage form can be broadly divided into two types: using a non-viral vector and using a viral vector.
- the target gene can be introduced into cells and tissues by the following method using a recombinant expression vector in which the target gene is incorporated into a conventional gene expression vector.
- Examples of a method for introducing a gene into cells include a monocalcium phosphate coprecipitation method and a direct injection method of DNA using a micro glass tube.
- a gene transfer method using an internal type liposome (internal type liposome), an electrostatic type liposome (electrostatic type liposom) ome) gene transfer method HVJ-ribosome method, improved HVJ-ribosome method (HVJ-AVE ribosome method), receptor Yuichi-mediated gene transfer method, transfer DNA molecules into cells with carrier (metal particles) by particle gun
- the recombinant expression vector can be taken into cells by subjecting it to any of the following methods: direct introduction of naked DNA, introduction of positively charged polymer, and the like.
- the naked-DNA direct transfer method is the simplest and is the preferred transfer method from this viewpoint.
- the HVJ-liposome method is a preferred mode of introduction because it has a much higher fusion activity with the cell membrane than the conventional liposome method.
- the HVJ is preferably the Z strain (available from ATCC), but basically other HVJ strains (eg, ATCC VR-907, ATCC VR-105, etc.) can also be used.
- the expression vector used here may be any expression vector as long as it is a vector capable of expressing the target gene in vivo.
- pCAGGS Gene 108, 193-200 (1991)
- PBK-CMV PBK-CMV
- pcDNA3.1 pcDNA3.1
- Zeo SV Zeo SV
- the two or more types of genes may be obtained by mixing two or more types of recombinant expression vectors prepared by incorporating the genes into separate expression vectors, simultaneously, or separately at time intervals. It can be introduced into a living body. It is also possible to introduce a single expression vector in which two or more types of genes are integrated in one expression vector.
- two or more recombinant expression vectors can be encapsulated and introduced in one liposome, or individual recombinant expression vectors can be encapsulated in separate liposomes.
- virus vector examples include a recombinant adenovirus, a retrovirus and the like. More specifically, for example, detoxified retrovirus, adenovirus, adeno-associated virus, herpes virus, vaccinia virus, box II
- adenovirus adeno-associated virus
- herpes virus vaccinia virus
- vaccinia virus box II
- viruses such as viruses, poliovirus, synvis virus, Sendai virus, SV40, and immunodeficiency virus (HIV)
- HIV immunodeficiency virus
- the adenovirus infection efficiency is much higher than when other virus vectors are used. From this viewpoint, it is preferable to use an adenovirus vector system. .
- two or more types of genes are mixed at the same time or at the same time by mixing the recombinant expression vectors incorporated in separate expression vectors. They can be introduced separately at intervals. It is also possible to introduce a single recombinant expression vector that incorporates two or more types of genes into one expression vector.
- two or more types of genes can be introduced into a living body using both the non-viral vector and the viral vector.
- the method of introducing the gene therapy agent of the present invention into a patient includes the J'fl method in which the gene therapy agent is directly introduced into the body, and a method in which a certain cell is removed from a human and the gene therapy agent is introduced into the cell outside the body. And there is a / ra method to return the cells to the body (Nikkei Science, April 1994, pp. 20-45, Monthly Pharmaceutical Affairs, 36 (1), 23-48, 1994, Experimental Medicine Special Edition, 12 (1 5), 1994, edited by The Japanese Society of Gene Therapy. Gene Therapy Development Research Handbook, NT-'S, 1999). In the present invention, the in 'ra method is preferred.
- the / z'TO method When administered by the / z'TO method, it can be administered by an appropriate route depending on the disease to be treated, the target organ, and the like. For example, it can be administered intravenously, intraarterially, subcutaneously, intradermally, intramuscularly, etc., or can be directly administered locally to the affected tissue itself.
- the dosage form may be various dosage forms (for example, liquids) suitable for each of the above administration forms.
- the injection can be prepared by a conventional method. For example, after dissolving in an appropriate solvent (a buffer solution such as PBS, physiological saline, sterile water, etc.), sterilize by filtration through a filter if necessary, Then, it can be prepared by filling in a sterile container. A conventional carrier or the like may be added to the injection, if necessary.
- ribosomes such as HVJ-liposomes can be in the form of liposomal preparations such as suspensions, freezers, and centrifugal concentrated freezers.
- a sustained-release preparation (such as a mini-pellet preparation) can be prepared and implanted near the affected area. It is also possible to administer continuously and gradually.
- the two or more types of recombinant expression vectors may be in the form of separate preparations, or may be in the form of a mixed preparation.
- each gene in the preparation can be appropriately adjusted depending on the disease to be treated, the age and weight of the patient, etc.
- each gene is 0.00001 to 100 mg, preferably 0. It is preferably administered once every few days to several months.
- a substance having a vasodilatory action and / or an inhibitory action on platelet aggregation a substance (such as a low molecular weight compound or a protein) that produces the substance and a gene encoding an angiogenic factor are used.
- the gene encoding an angiogenic factor is in the form of the above-described gene therapeutic agent.
- the low molecular weight compound or the like is in the form of a general pharmaceutical composition and is orally or parenterally administered.
- HGF gene and PG E 2 derivatives such as combinations of the VEGF gene and PG 1 2 derivative thereof al are.
- the low molecular weight compound or protein is already marketed as a vasodilator or a platelet aggregation inhibitor (antiplatelet agent), the administration method and dosage can be set according to the specifications. In general, the following administration forms and administration methods can be mentioned.
- the composition when administered orally, it can be administered in a dosage form commonly used in the art.
- it when administered parenterally, it can be administered in the form of topical administration (eg, transdermal), rectal administration, injection, nasal administration, and the like.
- topical administration eg, transdermal
- rectal administration injection, nasal administration, and the like.
- oral or rectal preparations examples include capsules, tablets, pills, powders, drops, suppositories, and liquid preparations.
- injection include sterile solutions or suspensions, emulsions and the like, and specific examples include water, a water-propylene glycol solution, a buffer solution, and 0.4 ° / physiological saline.
- topical preparation examples include creams, ointments, lotions, transdermals and the like.
- compositions and additives are formulated together with pharmaceutically acceptable excipients and additives by a method usually used in the art.
- Pharmaceutically acceptable excipients and additives include carriers, binders, flavors, buffers, thickeners, coloring agents, stabilizers, emulsifiers, dispersants, suspending agents, preservatives, pH control Agents, tonicity adjusting agents, infiltrating agents and the like.
- Pharmaceutically acceptable carriers include, for example, magnesium carbonate, lactose, pectin, starch, methylcellulose and the like.
- Such a pharmaceutical composition can be administered via an appropriate administration route depending on the disease to be treated, the target organ, and the like.
- it can be administered intravenously, intraarterially, subcutaneously, intradermally, intramuscularly, etc., or directly topically to the affected tissue itself.
- Oral administration and administration as a suppository are also possible.
- the dosage and number of administrations vary depending on symptoms, age, body weight, dosage form, etc., but are usually in the range of about 0.001 to about 50 mg / day, preferably about 0.000 mg / day for adults.
- the range of 1 to about 100 mg can be administered once or in several divided doses.
- Pharmaceutical compositions containing the above low molecular weight compounds and proteins as active ingredients are It can be administered simultaneously with a gene therapy agent containing a gene encoding a nascent factor, or can be administered separately at time intervals.
- the pharmaceutical composition for angiogenesis therapy of the present invention can be applied to all diseases requiring angiogenesis therapy.
- diseases requiring angiogenesis therapy include ischemic disease or arterial disease, and more specifically, heart disease includes ischemic heart disease, myocardial infarction, acute myocardial infarction, cardiomyopathy, angina, unstable angina, Coronary arteriosclerosis, heart failure, etc.
- limb ischemic diseases include obstructive arteriosclerosis (AS0), Bajaja disease, vascular injury, arterial embolism, arterial thrombosis, organ artery occlusion, aneurysm And the like.
- Other examples include cerebrovascular disorders.
- cerebrovascular disorder examples include cerebral vascular occlusion, cerebral infarction, cerebral thrombosis, cerebral embolism, cerebral apoplexy, cerebral hemorrhage, moyamoya disease, cerebrovascular dementia, Alzheimer's dementia, sequelae of cerebral hemorrhage or sequelae of cerebral infarction.
- the pharmaceutical composition of the present invention is effectively used particularly for atherosclerosis obliterans among these diseases.
- the present invention provides angiogenesis by a gene encoding an angiogenic factor, which comprises, as an active ingredient, a substance having a vasodilatory action and / or a platelet aggregation inhibitory action, and a substance that produces the substance. It also provides action enhancers.
- the substance which is the active ingredient of the pharmaceutical composition for angiogenesis therapy of the present invention, has an effect of enhancing the angiogenic action of a gene encoding an angiogenic factor. Therefore, as described above, it can be used alone as a component of a pharmaceutical composition for angiogenesis therapy, or can be used alone as an enhancer for enhancing angiogenic action by a gene encoding an angiogenic factor.
- the enhancer of the present invention is effectively used when the effect of the gene encoding the angiogenic factor is insufficient.
- the enhancer of the present invention may be composed of only one component (substance), or may be used in combination of a plurality of components (substances).
- active ingredient of the enhancer of the present invention include the above-mentioned PGIS gene and COX gene, PGI 2 , PGE, and derivatives thereof. And preferably a PGIS gene.
- examples of angiogenic factors include HGF and VEGF as described above.
- the method for administering the enhancer of the present invention, the dosage form, and the indications are the same as those of the pharmaceutical composition for angiogenesis therapy.
- the present invention also provides an angiogenic agent containing the PGIS gene as an active ingredient. That is, in the present invention, it has been found for the first time that an angiogenic action is caused by the single administration of the PGIS gene. This is a novel effect that was not known until now, and for the first time, this finding has made it clear that the PGIS gene can be used as an angiogenic agent.
- the angiogenic agent of the present invention can be used for all diseases requiring angiogenesis as described above (ischemic disease or arterial disease).
- the administration method and administration form are the same as those of the above-mentioned pharmaceutical composition for angiogenesis therapy.
- the ets-1 gene is effective as a gene therapy agent for angiogenesis therapy. That is, as shown in the Examples below, the angiogenesis effect was observed by the single administration of the et s_l gene, and the case where each was administered alone by the combined use of the et s-1 gene and the HGF gene. In comparison, it was revealed that angiogenesis was further promoted.
- et s-1 is a transcriptional regulator whose expression is commonly promoted by the action of angiogenesis factors such as HGF, VEGF, bFGF, and EGF.
- the angiogenesis factor is mediated by et s-1. It is known that it activates various factors related to angiogenesis (J. Cell. Physiol., 169, 522-531 (1996), Molecular Medicine of HGF, Medical Review, 179-185 (1998) )). Therefore, it is considered that a similar combination effect can be obtained when not only the HGF gene but also an angiogenic factor gene other than HGF such as VEGF is used in combination with the ets-1 gene.
- the present invention provides a novel pharmaceutical composition for angiogenesis therapy, which relates to providing the et s-1 gene alone or in combination with another angiogenic factor.
- the following three forms can be exemplified.
- a pharmaceutical composition for angiogenesis therapy comprising the ets-1 gene and another gene encoding an angiogenic factor as active ingredients.
- the “ets-1 gene” refers to a gene encoding ets-1 (ets-1 protein).
- a product obtained by incorporating the et ss-1 gene into an expression plasmid so that it can be expressed is sometimes simply referred to as "et s-1 gene”.
- et s-1 gene a product obtained by incorporating the et ss-1 gene into an expression plasmid so that it can be expressed.
- et s-1 gene a product obtained by incorporating the et ss-1 gene into an expression plasmid so that it can be expressed.
- et s-1 gene a product obtained by incorporating the et ss-1 gene into an expression plasmid so that it can be expressed.
- the cDNA of human ets-1 registered in GenBank Acc. No. J04101 and described in Pro Natl. Acad. Sci. USA, 85 (21), 7862-7866 (1988) was used.
- the ets-1 gene can be cloned by the same method as that for the HGF gene or VEGF gene described above. Further, the ets_1 gene of the present invention is not limited to the natural type, and is included in the category of the ets-1 gene of the present invention as long as the expressed protein is a gene having substantially the same action as ets-11. .
- Such an ets-1 gene is in the form of a gene therapy agent similar to the aforementioned HGF gene and PGIS gene. Further, the method of introduction into the living body, the amount of introduction, the form of the preparation, and the like are the same as those of the HGF gene and the PGIS gene.
- these two or more types of genes are as follows: Dosage form. That is, when a non-viral vector is used, individual recombinant expression vectors prepared by incorporating them into separate expression vectors are mixed and introduced into a living body simultaneously or separately at time intervals. can do. It is also possible to introduce a single expression vector incorporating two or more types of genes into one expression vector.
- the individual recombinant expression vectors can be encapsulated in one ribosome and introduced, or the individual recombinant expression vectors can be encapsulated in separate ribosomes and introduced. It is.
- the recombinant expression vector in which two or more types of genes are incorporated in separate expression vectors is mixed. They can be introduced at the same time or separately at time intervals. It is also possible to introduce a single recombinant expression vector in which two or more genes have been integrated into one expression vector.
- any gene for an angiogenic factor used in combination with the ets-1 gene can be any gene that encodes a protein, polypeptide, or a portion thereof that can induce the formation of new blood vessels.
- the HGF gene and the VEGF gene are preferred, and the HGF gene is more preferred.
- the ets-1 gene of the present invention can be used alone as an enhancer for enhancing the angiogenic effect of a gene encoding an angiogenic factor such as HGF or VEGF as described in (2) above. it can.
- Such an enhancer containing the ets-1 gene as an effective component is effectively used when the effect of the gene encoding an angiogenic factor is insufficient.
- it is effectively used as an enhancer for enhancing the action of the HGF gene.
- the ets_1 gene of the present invention can be used alone as an angiogenic agent as described in (3) above. Thus, even when the ets-1 gene is used alone, the same administration method and administration form as the above-mentioned gene therapy agent are used.
- ischemic disease or arterial disease specifically include ischemic disease or arterial disease, and more specifically, heart disease and Ischemic heart disease, myocardial infarction, acute myocardial infarction, cardiomyopathy, angina, unstable angina, coronary atherosclerosis, heart failure, etc. (AS0), Baja disease, vascular injury, arterial embolism, arterial thrombosis, organ arterial occlusion, aneurysm, and the like.
- Other examples include cerebrovascular disorders.
- cerebrovascular disorders include cerebrovascular obstruction, cerebral infarction, cerebral thrombosis, cerebral embolism, stroke, cerebral hemorrhage, moyamoya disease, cerebrovascular dementia, Alzheimer's dementia, sequelae of cerebral hemorrhage or sequelae of cerebral infarction.
- the pharmaceutical composition containing the ets-11 gene of the present invention as an active ingredient is effectively used particularly for atherosclerosis obliterans among these diseases.
- Figure 1 shows that after administering each gene (control, HGF gene, PGIS gene, HGF gene + PGIS gene) to the mouse lower limb ischemia AS0 model, the blood flow of the lower limb was measured using a laser Doppler imager.
- 4 is a graph showing the result of examining the change over time of the left-right ratio.
- Figure 2 shows the measurement of lower extremity blood flow using a laser Doppler imager after administration of each gene (control, HGF gene, PGIS gene, HGF gene + PGIS gene) to the mouse lower limb ischemia AS0 model.
- 4 is a graph showing the results of a time-course study of the rate of increase of the left-right ratio with respect to that before gene administration.
- Figure 3 shows the results of examining the number of ischemic limb intramuscular capillaries after administration of each gene (control, HGF gene, PGIS gene, HGF gene + PGIS gene) to the mouse lower limb ischemia AS0 model. It is a graph shown.
- Figure 4 shows that the lower extremity blood flow was monitored by laser Doppler after administration of each gene (control, HGF gene, ets-1 gene, HGF gene + ets-1 gene) to the rat lower limb ischemia AS0 model.
- 4 is a graph showing the result of measurement using an imager to examine the rate of increase in the blood flow ratio between the right and left legs.
- Figure 5 shows the ischemic limb intramuscular capillary density after administration of each gene (control, HGF gene, ets-1 gene, HGF gene + ets-1 gene) to the rat lower limb ischemia AS0 model.
- 6 is a graph showing the results of measuring the.
- Figure 6 shows rat HGF concentration in ischemic limb muscle after administration of each gene (control, HGF gene, ets-1 gene, HGF gene + ets-1 gene) to the rat lower limb ischemia AS0 model.
- 9 is a graph showing the results of examining.
- FIG. 7 is a graph showing the results of examining rat HGF concentrations in ischemic limb muscles after administration of the ets-1 gene to the rat lower limb ischemia AS0 model.
- FIG. 8 is a graph showing the results of examining the human VEGF concentration in the ischemic lower limb muscle after administering the PGIS gene, the VEGF gene, or the VEGF gene and the PGIS gene to the mouse lower limb ischemia AS0 model. is there.
- FIG. 9 is a graph showing LDI blood flow ratios of untreated right lower limb (normal) and left lower limb (AS0) 10 days after surgery for a mouse lower limb ischemia AS0 model.
- Figure 10 shows the rate of increase in blood flow due to LDI in ischemic lower limb muscle 2 weeks after administration of PGIS gene, VEGF gene, or VEGF gene and PGIS gene to the mouse lower limb ischemia AS0 model. It is a graph which shows the result of having investigated.
- Figure 11 shows the rate of increase in blood flow due to LDI in ischemic lower limb muscle 4 weeks after administration of PGIS gene, VEGF gene, or VEGF gene and PGIS gene to the mouse lower limb ischemia AS0 model. It is a graph which shows the result of having investigated.
- Figure 12 shows a frozen section of ischemic lower limb muscle 4 weeks after administration of PGIS gene and HGF gene, VEGF gene, or VEGF gene and PGIS gene to mouse lower limb ischemia AS0 model. It is a photograph stained by force phosphatase staining.
- FIG. 13 is a graph showing the results of examining the capillary density of the mouse lower limb ischemia AS0 model 4 weeks after administration of the PGIS gene, the VEGF gene, or the VEGF gene and the PGIS gene.
- the human HGF gene was obtained by cloning a human HGF cDNA (described in Japanese Patent Application Laid-Open No. 5-111383) by a conventional method, and then cloning the expression plasmid pcDNA3.1 (+) (with a cytomegalovirus (CMV) promoter). (Invitrogen) was used.
- Human PGIS gene, cDNA of human PGIS (BBRC 3 Vol .200, No.3 5 pl728-1734 (1994)) were cloned by the conventional method, the expression plasmid pCAGGS with this CMV Enhansa first and 5- Akuchin promoter ( Gene 108, 193-200 (1991)) was used.
- mice C57BL / 6J mice (8 weeks old, male) were used.
- the mice were anesthetized by intraperitoneal administration of Nembuil (10-fold dilution) in 200 1 and inhalation of ether if needed.
- the artery and vein of the left lower limb were ligated to produce a mouse lower limb ischemia AS0 model.
- the blood flow in both lower limbs was evaluated using a Laser Doppler Imager (LDI, MLDI5070, manufactured by Moor Instruments Ltd), and the ratio between left and right was calculated.
- the gene of the above (1) was administered in the form of a naked plasmid (500 zg) into the muscle of the left lower limb.
- FIG. 1 shows the change over time in the ratio of the blood flow in the left and right lower limbs measured by LDI.
- Figure 2 shows the percentage increase relative to the LDI ratio before gene administration.
- Administration of the PGIS gene improved blood flow after 2 weeks, but was almost equivalent to the control group after 4 weeks.
- Gene administration improved blood flow after two to four weeks.
- the combined use of the PGIS gene and the HGF gene significantly improved the blood flow unexpectedly and remarkably compared to the case where each gene was administered alone (2 weeks later: control: 100%, administration of the HGF gene) : 132%, PGIS gene administration: 125% HGF gene + PGIS gene administration: 177%, P-0.01; 4 weeks later: control: 100%, HGF gene administration: 150%, PGIS gene administration: 104%, HGF Gene + PGIS gene administration: 166%, P-0.01).
- Figure 3 shows the intramuscular capillary density 4 weeks after gene administration.
- Administration of the PGIS gene or HGF gene increased the capillary density.
- the combined use of the PGIS gene and the HGF gene significantly increased the capillary density compared to each gene alone.
- the same expression plasmid as in Example 1 was used as the expression plasmid having the human HGF gene.
- human ets-1 gene cDNA of human ets-1 (GenBank Acc.No.J041 01, Proc. Natl. Acad. Sci. USA, 85 (21), 7862-7866 (1988)) is used. The clone was inserted into a commercially available expression vector.
- Sprauge Dawley rats (12 weeks old, male) were used.
- One femoral artery was excised and a rat lower limb ischemia AS0 model was prepared.
- 100 g of each gene was administered to the left lower limb muscle using the HVJ-liposome method.
- Control group HGF gene single administration group, ets-1 gene single administration group, HGF gene and ets-1 gene combination group were set in 4 groups.
- Blood flow in both lower limbs was evaluated using a Laser Doppler Imager (LDI) before gene administration and 4 weeks after gene administration, and the rate of increase in the left-right blood flow ratio was calculated.
- LPI Laser Doppler Imager
- rat HGF concentration in ischemic limb muscle was measured using an ELISA kit (manufactured by Tokushu Immune Laboratory).
- ets-1 gene alone increased ets-1 binding activity in muscle tissue.
- administration of the ets-1 gene increased the rate of increase in the lower limb blood flow ratio measured using LDI (FIG. 4) and increased the intramuscular capillary density (FIG. 5). That is, the angiogenesis effect by the administration of the ets-1 gene alone and the efficacy on the AS0 model were shown.
- the HGF concentration in the ischemic limb muscle was elevated (FIGS. 6 and 7), which was considered to be one of the mechanisms by which the administration of the ets-1 gene was effective.
- the rat HGF concentration in rat ischemic limb muscle was measured, the rat HGF concentration was higher in the group that used the HGF gene and the ets-1 gene in combination than in the group that received the HGF gene alone.
- human VEGF165 cDNA (provided by Dr. Yonemitsu, Kyushu University Second Surgery) was cloned by a conventional method, and this was cloned into an expression plasmid pCAGGS (Gene 108) having CMV Enhansa-1 and / -actin motor. , 193-200 (1991)).
- Human PGIS gene cDNA of human PGIS (BBRC, Vol.200 3 No.3, pl728-1734 (1994)) was cloned by a conventional method, which CMV Enhansa first and /? - a Akuchin promoter evening one
- the expression plasmid pCAGGS (Gene 108, 193-200 (1991)) was used.
- mice C57BL / 6J mice (8 weeks old, male) were used. The mice were anesthetized by intraperitoneal administration of a 10-fold dilution of Nembu 200-1 intraperitoneally and inhaling ether if needed. Thereafter, the artery and vein of the left lower limb were ligated to produce a mouse lower limb ischemia AS0 model. After the evaluation, the above-mentioned gene (1) was administered in the form of a naked plasmid into the left lower limb muscle in the form of a naked plasmid.
- a control group to which nothing was administered
- a group to which VEGF gene was administered alone a group to which PGIS gene was administered alone
- a group to which VEGF gene and PGIS gene were combined.
- Each group contained four animals. Five days after administration of each plasmid to the left tibialis muscle, the concentration of human VEGF protein in the ischemic lower limb muscle was measured using an AN'ALYZA Immunoassay System human VEGF kit (GENZYME). (Fig. 8)
- a mouse lower limb ischemia AS0 model was prepared in the same manner as described above. Ten days later, the blood flow of both lower limbs was evaluated using a Laser Doppler Imager (LDI, MLDI5070, manufactured by Moor Instruments Ltd.), and the ratio of left and right was calculated (Fig. 9; right foot (normal), left lower limb). (AS0)). As a result, it was confirmed that the blood flow in the left lower limb was reduced to about 30% when the blood flow was normal in 100%. After the evaluation, the gene of the above (1) was administered to the left lower limb muscle in the form of a naked plasmid in an amount of 500 ⁇ g each.
- a control group receiving nothing, a VEGF gene alone
- a group a group administered PGIS gene alone
- a group combined with VEGF gene and PGIS gene a group administered PGIS gene alone
- Blood flow was evaluated using LDI two and four weeks after gene administration, and the rate of increase was calculated. Four weeks later, the muscles of the left lower limb were excised, frozen sections were prepared, stained with alkaline phosphatase (FIG. 12), and the capillary density in the muscle was measured. The significance test was performed by Fisher's PLSD method.
- Fig. 10 The increase rate of blood flow in the left lower limb measured by LDI after 2 weeks is shown in Fig. 10, and the increase rate after 4 weeks is shown in Fig. 4.
- PGIS gene and VEGF gene unexpectedly significantly improved blood flow compared to each gene alone (2 weeks later: control: 100, PGIS gene administration: 105 %, VEGF gene administration: 117%, VEGF gene + PGIS gene administration: 115%; After 4 weeks: control: 100, PGIS gene administration: 103%, VEGF gene administration: 130%, VEGF gene + PGIS gene administration: 169 %, P 0.0 0.0 1).
- FIG. 13 shows the intramuscular capillary density 4 weeks after the gene administration.
- VEGF gene administration increased capillary density.
- the combined use of the PGIS gene and the VEGF gene significantly increased the capillary density compared to each gene alone. (Control: so-called PGIS gene administration: 175%, VEGF gene administration: 221%, VEGF gene + PGIS gene administration: 338%, P-0001) o Industrial applicability
- a substance having a vasodilatory action and / or a platelet aggregation inhibitory action, and at least one selected from substances producing the substance, and a gene encoding an angiogenic factor are contained as active ingredients.
- a novel and highly effective pharmaceutical composition for angiogenesis therapy can be provided.
- genes that were not known to be used in angiogenesis therapy such as the prosucylcycline synthase gene and the ets-11 gene, can be applied to angiogenesis therapy.
- a pharmaceutical composition for angiogenesis therapy comprising these genes as active ingredients can be provided.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Marine Sciences & Fisheries (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Description
Claims
Priority Applications (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/312,435 US20030171287A1 (en) | 2000-06-27 | 2001-06-27 | Medicinal compositions for angiogenic therapy |
DE60134021T DE60134021D1 (de) | 2000-06-27 | 2001-06-27 | Pharmazeutische zubereitungen zur angiogenese-therapie |
AU6633801A AU6633801A (en) | 2000-06-27 | 2001-06-27 | Medicinal compositions for angiogenic therapy |
EP01943840A EP1300158B9 (en) | 2000-06-27 | 2001-06-27 | Pharmaceutical compositions for angiogenic therapy |
AU2001266338A AU2001266338B8 (en) | 2000-06-27 | 2001-06-27 | Pharmaceutical compositions for angiogenic therapy |
KR1020027017686A KR100798566B1 (ko) | 2000-06-27 | 2001-06-27 | 혈관 신생요법용 의약조성물 |
JP2002505039A JP5030124B2 (ja) | 2000-12-21 | 2001-06-27 | 血管新生療法用医薬組成物 |
CA002413768A CA2413768A1 (en) | 2000-06-27 | 2001-06-27 | Pharmaceutical compositions for angiogenic therapy |
NZ523613A NZ523613A (en) | 2000-06-27 | 2001-06-27 | Pharmaceutical compositions for angiogenic therapy |
US12/435,335 US7994151B2 (en) | 2000-06-27 | 2009-05-04 | Compositions and methods for angiogenic therapy utilizing genes encoding ets-1 |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2000192480 | 2000-06-27 | ||
JP2000-192480 | 2000-06-27 | ||
JP2000388624 | 2000-12-21 | ||
JP2000-388624 | 2000-12-21 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10312435 A-371-Of-International | 2001-06-27 | ||
US12/435,335 Division US7994151B2 (en) | 2000-06-27 | 2009-05-04 | Compositions and methods for angiogenic therapy utilizing genes encoding ets-1 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2002000258A1 true WO2002000258A1 (fr) | 2002-01-03 |
WO2002000258A8 WO2002000258A8 (fr) | 2003-01-23 |
Family
ID=26594742
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2001/005514 WO2002000258A1 (fr) | 2000-06-27 | 2001-06-27 | Compositions medicales de therapie angiogenique |
Country Status (10)
Country | Link |
---|---|
US (2) | US20030171287A1 (ja) |
EP (2) | EP1300158B9 (ja) |
KR (1) | KR100798566B1 (ja) |
CN (1) | CN1274365C (ja) |
AT (2) | ATE395071T1 (ja) |
AU (2) | AU2001266338B8 (ja) |
CA (1) | CA2413768A1 (ja) |
DE (1) | DE60134021D1 (ja) |
NZ (1) | NZ523613A (ja) |
WO (1) | WO2002000258A1 (ja) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002064165A1 (fr) * | 2001-02-13 | 2002-08-22 | Hisamitsu Pharmaceutical Co., Inc. | Inhibiteurs de la proliferation cellulaire comprenant un facteur de transcription ets ou un gene codant ce dernier |
WO2005021045A1 (ja) * | 2003-08-29 | 2005-03-10 | Anges Mg, Inc. | 針無注射器を用いた皮膚疾患の遺伝子治療 |
JP2007528365A (ja) * | 2004-03-09 | 2007-10-11 | 株式会社 東北テクノアーチ | 肝細胞増殖因子を含有する血管分化誘導促進剤 |
WO2011024480A1 (ja) | 2009-08-31 | 2011-03-03 | Hukuda Keiichi | 血管新生療法用医薬組成物 |
WO2020049286A1 (en) | 2018-09-03 | 2020-03-12 | Femtogenix Limited | Polycyclic amides as cytotoxic agents |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20010108053A (ko) * | 1999-10-29 | 2001-12-07 | 무라야마 마사노리 | 당뇨병성 허혈성 질환 유전자 치료 |
KR100562824B1 (ko) * | 2002-03-20 | 2006-03-23 | 주식회사 바이로메드 | 유전자 발현효율이 높으며 간세포 성장인자의 두 가지이형체를 동시에 발현하는 하이브리드 간세포 성장인자유전자 |
EP1567197B1 (en) * | 2002-12-02 | 2010-07-21 | AnGes MG, Inc. | Compositions for treating or preventing angiogenesis-dependent symptoms |
ATE493973T1 (de) | 2004-06-04 | 2011-01-15 | Teva Pharma | Irbesartan enthaltende pharmazeutische zusammensetzung |
US7608416B2 (en) * | 2004-12-07 | 2009-10-27 | The Trustees Of The University Of Pennsylvania | Targeting mPGES-1 as a treatment for inflammation which avoids cardiovascular risk |
US7252834B2 (en) * | 2005-04-25 | 2007-08-07 | Clemson University Research Foundation (Curf) | Elastin stabilization of connective tissue |
US20090202606A1 (en) * | 2008-01-25 | 2009-08-13 | Viromed Co., Ltd. | Treatment and Prevention of Cardiac Conditions Using Two or More Isoforms of Hepatocyte Growth Factor |
EP2257274A4 (en) * | 2008-02-21 | 2011-07-20 | Vatrix Medical Inc | TREATMENT OF ANEURYSMA USING A BIND WEAVE STABILIZING AGENT COMBINED WITH A DISPENSER |
BRPI0911511B8 (pt) * | 2008-04-09 | 2021-05-25 | Helixmith Co Ltd | formulação de dna liofilizadas para aumentar a expressão de dna de plasmídeo |
JP5725489B2 (ja) | 2008-06-27 | 2015-05-27 | 公立大学法人大阪市立大学 | 医療用組成物および医療用キット |
US20100016833A1 (en) * | 2008-07-15 | 2010-01-21 | Ogle Matthew F | Devices for the Treatment of Vascular Aneurysm |
US20100119605A1 (en) * | 2008-11-12 | 2010-05-13 | Isenburg Jason C | Compositions for tissue stabilization |
WO2011014563A1 (en) | 2009-07-29 | 2011-02-03 | Vatrix Medical, Inc. | Tissue stabilization for heart failure |
US20110218517A1 (en) * | 2009-10-09 | 2011-09-08 | Ogle Matthew F | In vivo chemical stabilization of vulnerable plaque |
US8444624B2 (en) | 2009-10-19 | 2013-05-21 | Vatrix Medical, Inc. | Vascular medical devices with sealing elements and procedures for the treatment of isolated vessel sections |
US8911468B2 (en) | 2011-01-31 | 2014-12-16 | Vatrix Medical, Inc. | Devices, therapeutic compositions and corresponding percutaneous treatment methods for aortic dissection |
WO2012158944A1 (en) | 2011-05-18 | 2012-11-22 | Vatrix Medical, Inc. | Coated balloons for blood vessel stabilization |
US9283241B2 (en) | 2012-07-10 | 2016-03-15 | Clemson University | Treatment to render implants resistant to diabetes |
BR112016008267A2 (pt) | 2013-10-22 | 2017-10-03 | Viromed Co Ltd | Composição para prevenir ou tratar esclerose lateral amiotrófica usando duas ou mais isoformas de fator de crescimento de hepatócito |
SG11201610142PA (en) | 2014-06-12 | 2017-01-27 | Tx Medic Ab | The use of dextran sulfate having an average molecular weight below 10000 da for inducing angiogenisis in a subject |
AU2019305221A1 (en) | 2018-07-19 | 2021-02-18 | Helixmith Co., Ltd. | Lyophilized pharmaceutical compositions for naked DNA gene therapy |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0727490A1 (en) * | 1994-04-28 | 1996-08-21 | Tanabe, tadashi | Human-origin prostacyclin synthase |
WO1997014307A1 (en) * | 1995-10-20 | 1997-04-24 | St. Elizabeth's Medical Center Of Boston, Inc. | Method for treating ischemic tissue |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5830879A (en) * | 1995-10-02 | 1998-11-03 | St. Elizabeth's Medical Center Of Boston, Inc. | Treatment of vascular injury using vascular endothelial growth factor |
JP3058828B2 (ja) * | 1996-03-15 | 2000-07-04 | 株式会社巴川製紙所 | 電子写真トナー用ポリエステル系樹脂、該樹脂の製造方法及び該樹脂を用いた電子写真用トナー |
US5785965A (en) * | 1996-05-15 | 1998-07-28 | The Board Of Trustees Of The Leland Stanford Junior Univ. | VEGF gene transfer into endothelial cells for vascular prosthesis |
US20030219380A1 (en) * | 1997-11-07 | 2003-11-27 | Annie Fong | Method of determining an efficacious dose of a drug |
AUPP459998A0 (en) * | 1998-07-09 | 1998-07-30 | Monash University | Modulation of haemopoietic cell activity and inflammation via the ets-1 gene and agents useful for same |
DE19940012A1 (de) | 1999-08-24 | 2001-03-08 | Karin Faerber | Neues Mittel aus mindestens zwei Komponenten, das zum einen Gefäßneubildung (Neoangiogense) induziert des weiteren jedoch auch Gefäßverschlüsse (Restenosen) verhindert, das Verfahren seiner Herstellung und seine Verwendung |
JP2001199903A (ja) * | 1999-11-09 | 2001-07-24 | Eizo Mori | 核酸含有複合体 |
WO2001058468A1 (en) * | 2000-02-09 | 2001-08-16 | Connetics Corporation | Use of relaxin to treat diseases related to vasoconstriction |
US6533541B1 (en) * | 2001-12-04 | 2003-03-18 | Honeywell International, Inc. | High energy particle arrestor for air turbine starters |
-
2001
- 2001-06-27 EP EP01943840A patent/EP1300158B9/en not_active Expired - Lifetime
- 2001-06-27 AU AU2001266338A patent/AU2001266338B8/en not_active Ceased
- 2001-06-27 KR KR1020027017686A patent/KR100798566B1/ko active IP Right Grant
- 2001-06-27 CA CA002413768A patent/CA2413768A1/en not_active Abandoned
- 2001-06-27 WO PCT/JP2001/005514 patent/WO2002000258A1/ja active IP Right Grant
- 2001-06-27 CN CNB018140068A patent/CN1274365C/zh not_active Expired - Fee Related
- 2001-06-27 US US10/312,435 patent/US20030171287A1/en not_active Abandoned
- 2001-06-27 DE DE60134021T patent/DE60134021D1/de not_active Expired - Lifetime
- 2001-06-27 AU AU6633801A patent/AU6633801A/xx active Pending
- 2001-06-27 AT AT01943840T patent/ATE395071T1/de not_active IP Right Cessation
- 2001-06-27 NZ NZ523613A patent/NZ523613A/en unknown
- 2001-06-27 EP EP07021738A patent/EP1889633B1/en not_active Expired - Lifetime
- 2001-06-27 AT AT07021738T patent/ATE530197T1/de not_active IP Right Cessation
-
2009
- 2009-05-04 US US12/435,335 patent/US7994151B2/en not_active Expired - Fee Related
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0727490A1 (en) * | 1994-04-28 | 1996-08-21 | Tanabe, tadashi | Human-origin prostacyclin synthase |
WO1997014307A1 (en) * | 1995-10-20 | 1997-04-24 | St. Elizabeth's Medical Center Of Boston, Inc. | Method for treating ischemic tissue |
Non-Patent Citations (3)
Title |
---|
HE H. ET AL.: "Vascular endothelial growth factor signals endothelial cell production of nitric oxide and prostacyclin through Flk-1/KDR activation of c-Src", J. BIOL. CHEM., vol. 274, no. 35, 1999, pages 25130 - 25135, XP002946220 * |
JONES M.K. ET AL.: "Inhibition of angiogenesis by non-steroidal anti-inflammatory drugs: Insight into mechanisms and implications for cancer growth and ulcer healing", NAT. MED., vol. 5, no. 12, 1999, pages 1418 - 1423, XP002946221 * |
MASAHIKO TSUJII: "COX to kekkan shinsei", IGAKU NO AYUMI, vol. 193, no. 4, April 2000 (2000-04-01), pages 245 - 248, XP002946222 * |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002064165A1 (fr) * | 2001-02-13 | 2002-08-22 | Hisamitsu Pharmaceutical Co., Inc. | Inhibiteurs de la proliferation cellulaire comprenant un facteur de transcription ets ou un gene codant ce dernier |
WO2005021045A1 (ja) * | 2003-08-29 | 2005-03-10 | Anges Mg, Inc. | 針無注射器を用いた皮膚疾患の遺伝子治療 |
JPWO2005021045A1 (ja) * | 2003-08-29 | 2006-10-26 | アンジェスMg株式会社 | 針無注射器を用いた皮膚疾患の遺伝子治療 |
JP2007528365A (ja) * | 2004-03-09 | 2007-10-11 | 株式会社 東北テクノアーチ | 肝細胞増殖因子を含有する血管分化誘導促進剤 |
WO2011024480A1 (ja) | 2009-08-31 | 2011-03-03 | Hukuda Keiichi | 血管新生療法用医薬組成物 |
CN102573924A (zh) * | 2009-08-31 | 2012-07-11 | 福田惠一 | 血管生成疗法用医药组合物 |
JP5779750B2 (ja) * | 2009-08-31 | 2015-09-16 | 恵一 福田 | 血管新生療法用医薬組成物 |
US11298386B2 (en) | 2009-08-31 | 2022-04-12 | Tadashi Tanabe | Drug composition for angiogenesis therapy |
US11666615B2 (en) | 2009-08-31 | 2023-06-06 | Tadashi Tanabe | Method for inducing production of vascular endothelial growth factor |
WO2020049286A1 (en) | 2018-09-03 | 2020-03-12 | Femtogenix Limited | Polycyclic amides as cytotoxic agents |
Also Published As
Publication number | Publication date |
---|---|
EP1889633B1 (en) | 2011-10-26 |
US20030171287A1 (en) | 2003-09-11 |
NZ523613A (en) | 2005-02-25 |
AU6633801A (en) | 2002-01-08 |
EP1300158B1 (en) | 2008-05-14 |
EP1889633A1 (en) | 2008-02-20 |
KR100798566B1 (ko) | 2008-01-28 |
US7994151B2 (en) | 2011-08-09 |
ATE530197T1 (de) | 2011-11-15 |
DE60134021D1 (de) | 2008-06-26 |
US20100240735A1 (en) | 2010-09-23 |
CA2413768A1 (en) | 2002-01-03 |
CN1446105A (zh) | 2003-10-01 |
EP1300158A4 (en) | 2005-04-13 |
AU2001266338B8 (en) | 2006-12-14 |
EP1300158B9 (en) | 2008-11-19 |
CN1274365C (zh) | 2006-09-13 |
AU2001266338B2 (en) | 2006-11-09 |
WO2002000258A8 (fr) | 2003-01-23 |
EP1300158A1 (en) | 2003-04-09 |
KR20030014391A (ko) | 2003-02-17 |
ATE395071T1 (de) | 2008-05-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7994151B2 (en) | Compositions and methods for angiogenic therapy utilizing genes encoding ets-1 | |
Segura-Ibarra et al. | Rapamycin nanoparticles localize in diseased lung vasculature and prevent pulmonary arterial hypertension | |
KR100768023B1 (ko) | 뇌혈관 장애를 위한 유전자 치료 | |
WO2003063911A1 (fr) | Compositions pharmaceutiques contenant un leurre et procede d'utilisation | |
KR20010108053A (ko) | 당뇨병성 허혈성 질환 유전자 치료 | |
JP5300157B2 (ja) | 血管新生療法用医薬組成物 | |
KR20160102069A (ko) | 생체내에서 세포에 활성 텔로머라제를 제공하기 위한 조성물 및 방법 | |
US10208103B2 (en) | Use of HDL-related molecules to treat and prevent proinflammatory conditions | |
Zhang et al. | Sequential and timely transfection of hepatocyte growth factor and monocyte chemotactic protein-1 ameliorates hyperkinetic pulmonary artery hypertension in rabbits | |
US11666615B2 (en) | Method for inducing production of vascular endothelial growth factor | |
JP2005320251A (ja) | 血管新生剤および抗血管新生剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 2002 505039 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2413768 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020027017686 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001266338 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 523613 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001943840 Country of ref document: EP |
|
CFP | Corrected version of a pamphlet front page | ||
CR1 | Correction of entry in section i | ||
WWE | Wipo information: entry into national phase |
Ref document number: 018140068 Country of ref document: CN |
|
WWP | Wipo information: published in national office |
Ref document number: 1020027017686 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 2001943840 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10312435 Country of ref document: US |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: 523613 Country of ref document: NZ |
|
WWG | Wipo information: grant in national office |
Ref document number: 523613 Country of ref document: NZ |
|
WWG | Wipo information: grant in national office |
Ref document number: 2001943840 Country of ref document: EP |